Aikium Inc.
Aikium is a biotechnology company leveraging its proprietary Yotta-ML² platform, the world's first AI-powered trillion-molecule screening system, to unlock the undruggable proteome. This platform utilizes a deep learning engine and a synthetic biology platform, combined with AI-designed protein language models, to achieve unmatched scale and target-agnostic capabilities, enabling therapeutic breakthroughs in months rather than years. Aikium differentiates itself by targeting regions inaccessible to traditional antibodies and small molecules, fostering high-impact partnerships with leading pharma and academic institutions, and boasting a proven team with leadership experience from NVIDIA, Harvard, 10X Genomics, NIH, and the Wyss Institute. Their mission is to deliver 100 breakthrough therapies within the next decade, with a focus on oncology, immune disorders, and other challenging diseases.
Aikium Inc.
Aikium is a biotechnology company leveraging its proprietary Yotta-ML² platform, the world's first AI-powered trillion-molecule screening system, to unlock the undruggable proteome. This platform utilizes a deep learning engine and a synthetic biology platform, combined with AI-designed protein language models, to achieve unmatched scale and target-agnostic capabilities, enabling therapeutic breakthroughs in months rather than years. Aikium differentiates itself by targeting regions inaccessible to traditional antibodies and small molecules, fostering high-impact partnerships with leading pharma and academic institutions, and boasting a proven team with leadership experience from NVIDIA, Harvard, 10X Genomics, NIH, and the Wyss Institute. Their mission is to deliver 100 breakthrough therapies within the next decade, with a focus on oncology, immune disorders, and other challenging diseases.